Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
18.41
+0.06 (0.33%)
Nov 22, 2024, 4:00 PM EST - Market closed
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for SBRA stock have an average target of 19, with a low estimate of 17 and a high estimate of 21. The average target predicts an increase of 3.20% from the current stock price of 18.41.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 11, 2024.
Analyst Ratings
The average analyst rating for SBRA stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 10 | 11 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | -2.23% | Oct 11, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Initiates $16 → $20 | Hold → Buy | Initiates | $16 → $20 | +8.64% | Oct 1, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $17 → $20 | Hold → Strong Buy | Upgrades | $17 → $20 | +8.64% | Sep 13, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | -2.23% | Sep 4, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | -7.66% | Aug 26, 2024 |
Financial Forecast
Revenue This Year
697.00M
Revenue Next Year
733.17M
from 697.00M
Increased by 5.19%
EPS This Year
0.54
from 0.06
Increased by 808.62%
EPS Next Year
0.70
from 0.54
Increased by 28.62%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 739.2M | 802.1M | 845.0M | ||
| Avg | 697.0M | 733.2M | 772.1M | ||
| Low | 646.0M | 666.8M | 681.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 15.1% | 15.2% | ||
| Avg | - | 5.2% | 5.3% | ||
| Low | - | -4.3% | -7.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.58 | 0.76 | 0.77 |
| Avg | 0.54 | 0.70 | 0.73 |
| Low | 0.49 | 0.59 | 0.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 870.6% | 39.8% | 10.2% |
| Avg | 808.6% | 28.6% | 5.6% |
| Low | 723.6% | 8.8% | 0.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.